Argenx wants to keep main asset to itself
Last year, Argenx became Danish Leo Pharma's first biotech partner, but the Belgian company's strategy is actually focused on avoiding partnerships as much as possible.
In 2017, the alliance with Belgian biotech firm Argenx marked Leo Pharma's first encounter with biological therapies, and since then the Danish dermatology group has continued on this path.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Leo’s bet on biologics progresses as planned
For abonnenter
